Display options
Cite
Hilburn C, Nejtek VA, Underwood WA, et al. Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?. Neuropsychiatr Dis Treat. 2011;7:357-64doi: 10.2147/NDT.S18953.
Hilburn, C., Nejtek, V. A., Underwood, W. A., Singh, M., Patel, G., Gangwani, P., & Forster, M. J. (2011). Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?. Neuropsychiatric disease and treatment, 7357-64. https://doi.org/10.2147/NDT.S18953
Hilburn, Craig, et al. "Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?." Neuropsychiatric disease and treatment vol. 7 (2011): 357-64. doi: https://doi.org/10.2147/NDT.S18953
Hilburn C, Nejtek VA, Underwood WA, Singh M, Patel G, Gangwani P, Forster MJ. Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?. Neuropsychiatr Dis Treat. 2011;7:357-64. doi: 10.2147/NDT.S18953. Epub 2011 Jun 21. PMID: 21792305; PMCID: PMC3140291.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2011;7:357-64. doi: 10.2147/NDT.S18953. Epub 2011 Jun 21.

Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?.

Neuropsychiatric disease and treatment

Craig Hilburn, Vicki A Nejtek, Wendy A Underwood, Meharvan Singh, Gauravkumar Patel, Pooja Gangwani, Michael J Forster

Affiliations

  1. University of North Texas Health Science Center at Fort Worth, TX, USA.

PMID: 21792305 PMCID: PMC3140291 DOI: 10.2147/NDT.S18953

Abstract

BACKGROUND: Data suggests that brain-derived neurotropic factor (BDNF) plays a neuroadaptive role in addiction. Whether serum BDNF levels are different in alcohol or psychostimulants as a function of craving is unknown. Here, we examined craving and serum BDNF levels in persons with alcohol versus psychostimulant dependence. Our goals were to explore BDNF as an objective biomarker for 1) craving 2) abstinence, and 3) years of chronic substance use.

METHODS: An exploratory, cross-sectional study was designed. Men and women between 20-65 years old with alcohol, cocaine, or methamphetamine dependence were eligible. A craving questionnaire was used to measure alcohol, cocaine and methamphetamine cravings. Serum levels of BDNF were measured using enzyme linked immunoassay. Analysis of variance, chi-square, and correlations were performed using a 95% confidence interval and a significance level of P < 0.05.

RESULTS: We found a significant difference in the mean craving score among alcohol, cocaine and methamphetamine dependent subjects. There were no significant influences of race, gender, psychiatric disorder or psychotropic medication on serum BDNF levels. We found that among psychostimulant users BDNF levels were significantly higher in men than in women when the number of abstinent days was statistically controlled. Further, a significant correlation between serum BDNF levels and the number of abstinent days since last psychostimulant use was found.

CONCLUSION: These data suggest that BDNF may be a biomarker of abstinence in psychostimulant dependent subjects and inform clinicians about treatment initiatives. The results are interpreted with caution due to small sample size and lack of a control group.

Keywords: BDNF; alcohol; cocaine; craving; methamphetamine

References

  1. J Clin Psychiatry. 2008 Aug;69(8):1257-66 - PubMed
  2. Neurosci Lett. 2004 Nov 16;371(1):79-83 - PubMed
  3. Neuromolecular Med. 2004;5(1):69-83 - PubMed
  4. J Psychiatr Res. 2007 Dec;41(12):979-90 - PubMed
  5. Nat Neurosci. 2007 Aug;10(8):1029-37 - PubMed
  6. J Neurosci. 2004 Feb 18;24(7):1604-11 - PubMed
  7. Int J Neuropsychopharmacol. 2010 Feb;13(1):1-4 - PubMed
  8. Minerva Psichiatr. 1981 Jan-Mar;22(1):7-12 - PubMed
  9. J Psychiatr Res. 2009 Sep;43(14):1171-4 - PubMed
  10. Ageing Res Rev. 2004 Nov;3(4):407-30 - PubMed
  11. Brain Res Mol Brain Res. 2005 Oct 31;140(1-2):86-90 - PubMed
  12. Neuropsychopharmacology. 2008 Jan;33(1):73-83 - PubMed
  13. J Neurochem. 2003 Jun;85(6):1604-13 - PubMed
  14. Alcohol Clin Exp Res. 2004 Nov;28(11):1609-12 - PubMed
  15. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 - PubMed
  16. C R Seances Soc Biol Fil. 1976;170(5):1056-63 - PubMed
  17. Neurosci Lett. 2002 Aug 16;328(3):261-4 - PubMed
  18. Nature. 1991 Mar 21;350(6315):230-2 - PubMed
  19. Rev Neurosci. 2001;12(2):95-110 - PubMed
  20. J Neurosci. 1994 Nov;14(11 Pt 1):6763-7 - PubMed
  21. Science. 2006 Feb 10;311(5762):864-8 - PubMed
  22. Psychiatry Clin Neurosci. 2010 Aug;64(4):341-57 - PubMed
  23. Prog Neurobiol. 2007 Feb;81(2):89-131 - PubMed
  24. Curr Opin Pharmacol. 2005 Feb;5(1):9-19 - PubMed
  25. Alcohol Alcohol. 2008 May-Jun;43(3):241-5 - PubMed
  26. Neuropharmacology. 1998 Dec;37(12):1553-61 - PubMed
  27. Drug Alcohol Depend. 1993 Dec;34(1):19-28 - PubMed
  28. J Clin Psychopharmacol. 2003 Aug;23(4):384-8 - PubMed
  29. Learn Mem. 2003 Mar-Apr;10(2):86-98 - PubMed
  30. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):181-4 - PubMed
  31. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1256-60 - PubMed
  32. J Psychopharmacol. 2007 Nov;21(8):820-5 - PubMed
  33. J Exp Med. 1999 Mar 1;189(5):865-70 - PubMed
  34. Diabetes. 2000 Mar;49(3):436-44 - PubMed
  35. Annu Rev Neurosci. 2001;24:677-736 - PubMed
  36. Drug Alcohol Depend. 2006 Jul 27;83(3):233-7 - PubMed
  37. Exp Neurol. 1999 Dec;160(2):500-7 - PubMed

Publication Types

Grant support